%A Xin,Wei %A Zhao,Chaoran %A Jiang,Longyang %A Pei,Dongmei %A Zhao,Lin %A Zhang,Chengpu %D 2021 %J Pathology and Oncology Research %C %F %G English %K Epithelial-mesenchymal transition (EMT),HNSCC,mRNAs,prognostic,Survival %Q %R 10.3389/pore.2021.585192 %W %L %M %P %7 %8 2021-March-29 %9 Original Research %# %! Prognostic biomarker in HNSCC %* %< %T Identification of a Novel Epithelial–Mesenchymal Transition Gene Signature Predicting Survival in Patients With HNSCC %U https://www.por-journal.com/articles/10.3389/pore.2021.585192 %V 27 %0 JOURNAL ARTICLE %@ 1532-2807 %X Head and neck squamous cell cancer (HNSCC) is one of the most common types of cancer worldwide. There have been many reports suggesting that biomarkers explored via database mining plays a critical role in predicting HNSCC prognosis. However, a single biomarker for prognostic analysis is not adequate. Additionally, there is growing evidence indicating that gene signature could be a better choice for HNSCC prognosis. We performed a comprehensive analysis of mRNA expression profiles using clinical information of HNSCC patients from The Cancer Genome Atlas (TCGA). Gene Set Enrichment Analysis (GSEA) was performed, and we found that a set of genes involved in epithelial mesenchymal transition (EMT) contributed to HNSCC. Cox proportional regression model was used to identify a four-gene (WIPF1, PPIB, BASP1, PLOD2) signature that were significantly associated with overall survival (OS), and all the four genes were significantly upregulated in tumor tissues. We successfully classified the patients with HNSCC into high-risk and low-risk groups, where in high-risk indicated poorer patient prognosis, indicating that this gene signature might be a novel potential biomarker for the prognosis of HNSCC. The prognostic ability of the gene signature was further validated in an independent cohort from the Gene Expression Omnibus (GEO) database. In conclusion, we identified a four-EMT-based gene signature which provides the potentiality to serve as novel independent biomarkers for predicting survival in HNSCC patients, as well as a new possibility for individualized treatment of HNSCC.